https://imaginab.com/news-events/conference/eanm-25-world-leading-meeting-39th-annual-congress-of-the-european-association-of-nucear-medicine2025-08-20T15:16:39-07:00weekly0.5https://imaginab.com/news-events/conference/2025-snmmi-annual-meeting2025-02-26T13:16:35-08:00weekly0.5https://imaginab.com/news-events/conference/2025-asco-annual-meeting2025-05-22T14:37:59-07:00weekly0.5https://imaginab.com/news-events/conference/american-association-for-cancer-research-aacr-annual-meeting-20252025-04-15T08:16:46-07:00weekly0.5https://imaginab.com/news-events/conference/io3602025-02-26T13:16:58-08:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/io360-revised.PNGIo360+revisedhttps://imaginab.com/news-events/conference/bio-europe-spring2025-02-26T12:29:11-08:00weekly0.5https://imaginab.com/news-events/conference/emim-20252025-02-26T13:06:41-08:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/shutterstock_2416846143.jpgShutterstock+2416846143https://imaginab.com/news-events/news/imaginab-enters-agreement-to-support-investigator-initiated-trial-at-memorial-sloan-kettering-cancer-center2025-02-11T07:56:18-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-inc-innovative-biologics-technology-platform-acquired-by-telix-to-enable-next-generation-therapeutic-assets-discovery2025-01-20T15:18:22-08:00weekly0.5https://imaginab.com/news-events/conference/esmo-immuno-oncology-summit2024-11-14T15:58:19-08:00weekly0.5https://imaginab.com/news-events/conference/66th-ash-annual-meeting-exposition2024-11-13T14:47:49-08:00weekly0.5https://imaginab.com/news-events/conference/sitc-2024-39th-annual-meeting2024-10-17T08:15:29-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/houston-tx.jpg.pngHouston+tx+jpghttps://imaginab.com/news-events/conference/eanm-2024-27th-annual-congress2024-10-08T09:17:49-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/pexels-moritz-kindler-1981732-3605249.jpgPexels+moritz+kindler+1981732+3605249https://s3.us-west-1.amazonaws.com/imaginab-website-assets/EANM24_logo_green-1.pngEANM24+logo+green+1https://imaginab.com/news-events/conference/esmo-congress-20242024-09-03T16:25:52-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/pexels-apasaric-1388030.jpgPexels+apasaric+1388030https://imaginab.com/news-events/news/clinical-trial-hopes-to-predict-response-to-cancer-treatment2024-08-29T08:51:11-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-building-a-legacy-of-excellence-in-radiopharmaceutical-development2024-08-26T15:09:29-07:00weekly0.5https://imaginab.com/news-events/conference/cambridge-healthtech-institutes-12-annual-immuno-oncology-summit2024-07-25T07:56:58-07:00weekly0.5https://imaginab.com/news-events/news/2024-h1-imaginab-newsletter2024-07-22T16:21:53-07:00weekly0.5https://imaginab.com/news-events/conference/bio-international-convention2024-05-17T12:27:02-07:00weekly0.5https://imaginab.com/news-events/conference/2024-snmmi-annual-meeting2024-05-15T08:33:39-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/pexels-souvenirpixels-1519088.jpgPexels+souvenirpixels+1519088https://imaginab.com/news-events/news/suzanne-bissonnette-sales-account-executive-joins-imaginab-to-expand-the-utilization-of-cd8-immunopet-in-i-o-clinical-trials2024-05-06T16:13:24-07:00weekly0.5https://imaginab.com/news-events/conference/2024-asco-annual-meeting2024-05-06T15:31:40-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/pexels-pixabay-161963.jpgPexels+pixabay+161963https://imaginab.com/news-events/conference/cambridge-healthtech-institutes-8th-annual-immuno-oncology-summit-europe-20242024-04-16T08:15:51-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/London-clock.jpgLondon+clockhttps://imaginab.com/news-events/conference/festival-of-biologics-usa2024-03-28T08:59:11-07:00weekly0.5https://imaginab.com/news-events/conference/aacr-annual-meeting2024-03-19T07:55:40-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/shutterstock_2266218267.jpgShutterstock+2266218267https://imaginab.com/news-events/conference/7th-world-theranostics-conference2024-03-14T09:50:45-07:00weekly0.5https://imaginab.com/news-events/news/matthew-hoover-director-of-sales-joins-imaginab-to-expand-the-utilization-of-cd8-immunopet-in-i-o-clinical-trials2024-01-30T07:37:31-08:00weekly0.5https://imaginab.com/news-events/news/2024-asco-gu-cancer-symposium-baseline-cd8-lymph-node-avidity-with-89-zr-crefmirlimab-in-patients-with-metastatic-renal-cell-carcinoma2024-01-29T11:42:04-08:00weekly0.5https://imaginab.com/news-events/news/molecular-imaging-in-clinical-trials-to-reduce-costs-of-failure2024-01-18T07:51:08-08:00weekly0.5https://imaginab.com/news-events/news/abstracts-presented-at-sitc-2023-featuring-cd8-immunopet2023-10-30T11:35:38-07:00weekly0.5https://imaginab.com/news-events/news/calmen-tihansky-promoted-to-sales-lead-marketing-manager2024-01-25T16:22:05-08:00weekly0.5https://imaginab.com/news-events/news/the-scientific-and-clinical-potential-of-89zr-crefmirlimab-berdoxam-cd8-immunopet-to-visualize-and-quantify-tumor-infiltrating-cd8-t-cells2023-09-29T15:22:48-07:00weekly0.5https://imaginab.com/news-events/news/integrating-molecular-imaging-in-immune-oncology2023-09-29T15:33:01-07:00weekly0.5https://imaginab.com/news-events/news/oncodesign-services-announce-access-to-imaginabs-cd8-immunopet-technology2023-06-27T09:35:59-07:00weekly0.5https://imaginab.com/news-events/news/radbound-umc-poster-cd8-immunopet-evaluated-to-assess-the-in-vivo-biodistribution-of-cd8-t-cells-in-hospitalized-covid-19-patients2023-06-27T09:36:43-07:00weekly0.5https://imaginab.com/news-events/news/immune-image-paper-preclinical-pet-ct-imaging-of-colon-infiltrating-cd4-t-cells-with-89zr-df-iab46-in-a-dextran-sodium-sulfate-induced-mouse-model-of-acute-and-chronic-ulcerative-colitis2023-06-27T09:36:51-07:00weekly0.5https://imaginab.com/news-events/news/asco-poster-cd8-cell-pet-imaging-with-89-zr-crefmirlimab-berdoxam-crefmirlimab-in-patients-with-metastatic-renal-cell-carcinoma-mrcc-receiving-checkpoint-inhibitors-cpis-association-with-response-and-tissue-cd8-expression2023-06-27T09:36:40-07:00weekly0.5https://imaginab.com/news-events/news/aacr-az-poster-a-first-assessment-of-cd8-pet-ct-with-89-zr-crefmirlimab-as-predictive-biomarker-for-response-to-standard-of-care-immunotherapy2023-06-27T09:36:47-07:00weekly0.5https://imaginab.com/news-events/news/imagio-consortium-receives-innovative-health-initiative-eur-24-million-grant-to-improve-cancer-treatments2023-06-16T15:20:14-07:00weekly0.5https://imaginab.com/news-events/news/snmmi-2023-presentation-logistics2023-06-08T13:09:32-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-advances-two-solid-tumor-radiopharmaceutical-therapy-rpt-candidates-towards-clinical-development2023-05-17T08:19:35-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-quibim-partner-to-revolutionize-immune-status-diagnosis-and-immunotherapy-prediction2023-05-01T13:55:21-07:00weekly0.5https://imaginab.com/news-events/news/new-analysis-of-phase-ii-data-at-aacr-assesses-imaginabs-investigational-cd8-immunopet-technologys-ability-to-predict-response-in-immunotherapy2023-04-13T14:51:47-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-execuites-new-license-and-supply-agreement-for-cd8-immunopet-technology-with-leucid-bio2023-04-12T00:20:09-07:00weekly0.5https://imaginab.com/news-events/event/society-for-immunotherapy-of-cancer-sitc2023-03-23T12:18:26-07:00weekly0.5https://imaginab.com/news-events/event/regulatory-affairs-professional-society-convergence-conference-raps-october-3-5-2023-montreal-qc2023-03-23T14:19:46-07:00weekly0.5https://imaginab.com/news-events/event/european-association-of-nuclear-medicine-eanm-sept-9-13-2023-vienna-austria2023-03-23T12:23:12-07:00weekly0.5https://imaginab.com/news-events/event/imaging-in-immuno-oncology-wmic-meeting-sept-5-9-2023-prague2023-03-23T12:18:49-07:00weekly0.5https://imaginab.com/news-events/event/targeted-radiopharmaceuticals-summit-us-july-25-27-2023-boston-ma2023-03-23T12:19:09-07:00weekly0.5https://imaginab.com/news-events/event/society-for-nuclear-medicine-and-molecular-imaging-snmmi-june-5-8-chicago-il2023-03-23T12:19:16-07:00weekly0.5https://imaginab.com/news-events/event/asco-annual-meeting-june-2-6-2023-chicago-il2023-03-23T12:19:26-07:00weekly0.5https://imaginab.com/news-events/event/aacr-annual-meeting-orlando-fl-april-14-19-20232023-03-23T10:38:28-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-launches-phase-ii-c-it-neo-trial-using-cd8-cell-imaging-to-investigate-neoadjuvant-immunotherapy2022-12-13T11:51:41-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-new-clinical-trial-at-hull-university-teaching-hospitals-nhs-trust-to-investigate-cd8-immunopet-in-patients-with-renal-cancer-and-malignant-melanoma2022-12-05T10:57:56-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-executes-new-license-and-supply-agreement-for-cd8-immunopet-technology-with-trisalus-life-sciences2022-11-21T11:04:38-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-executes-license-and-supply-agreement-for-cd8-immunopet-technology-with-dynamicure-biotechnology2022-11-15T08:12:39-08:00weekly0.5https://imaginab.com/news-events/news/parthenon-therapeutics-and-imaginab-announce-license-and-supply-agreement-to-advance-new-class-of-anti-cancer-therapies-clinical-development-program2022-11-10T08:45:13-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-first-patient-dosed-in-australia-in-phase-iib-ipredict-trial2022-10-25T08:25:24-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-cyclotek-enter-into-manufacturing-and-distribution-agreement-for-cd8-immunopet-agent-in-australia2022-10-14T17:25:37-07:00weekly0.5https://imaginab.com/news-events/news/a-transformational-year-imaginab-expands-pipeline-to-include-radiopharmaceutical-therapies-enters-multiple-partnerships-and-drives-forward-development-of-investigational-cd8-immunopet-agent2022-10-03T15:29:46-07:00weekly0.5https://imaginab.com/news-events/news/uc-davis-new-research-shows-how-total-body-pet-imaging-can-assess-the-immunological-response-to-covid-19-infections2022-08-10T10:32:06-07:00weekly0.5https://imaginab.com/news-events/news/women-of-color-in-biopharma-overcoming-barriers-and-fighting-for-a-seat-at-the-table-anna-wu-imaginab-founder-featured2022-07-20T15:28:59-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-duchembio-announce-manufacturing-and-distribution-partnership2022-06-22T09:52:40-07:00weekly0.5https://imaginab.com/news-events/news/society-of-nuclear-medicine-and-molecular-imaging-announces-2022-fellows-anna-wu-recognized-as-2022-fellow2022-06-21T10:33:20-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-pharmalogic-enter-into-manufacturing-and-distribution-agreement-for-cd8-immunopet-agent-zirconium-89-crefmirlimab-berdoxam-in-usa2022-06-11T08:07:23-07:00weekly0.5https://imaginab.com/news-events/news/monrol-and-imaginab-announce-supply-manufacturing-and-distribution-partnership2022-06-21T10:34:53-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-roche-have-entered-a-clinical-trial-supply-agreement-for-provision-of-atezolizumab-tecentriq-1-to-non-small-cell-lung-cancer-patients-enrolled-in-imaginabs-ipredict-phase-iib-study2022-06-21T10:35:03-07:00weekly0.5https://imaginab.com/news-events/news/ie-to-supply-clinical-doses-of-cd8-imaging-agent-to-biopharma-companies2022-06-21T10:35:16-07:00weekly0.5https://imaginab.com/news-events/webinar/breakfast-symposia-at-snmmi2022-06-11T13:38:05-07:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/2022SNMMI-AMlogoBK-002.jpg2022+SNMMI+A+Mlogo+BK+002https://imaginab.com/news-events/news/imaginab-and-yantai-dongcheng-pharmaceutical-group-sign-exclusive-license-agreement-to-commercialize-cd8-immunopet-agent-in-china-to-serve-pharma-and-healthcare-community2022-06-21T10:35:57-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-a-new-supply-agreement-with-invicro-to-offer-clinical-doses-of-cd8-investigational-immunopet-imaging-agent-for-immuno-oncology-preclinical-and-clinical-studies2022-06-21T10:36:53-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-new-supply-agreement-to-supply-genmab-a-s-with-its-investigational-cd8-immunopet-agent2022-06-21T10:37:07-07:00weekly0.5https://imaginab.com/news-events/news/cd8-target-pet-imaging-study-is-front-cover-news-of-the-journal-of-nuclear-medicine-in-may-2022-edition2022-05-04T10:09:56-07:00weekly0.5https://imaginab.com/news-events/event/imaginabs-ceo-ian-wilson-will-present-and-lead-a-discussion-hosted-by-the-oxford-global-entitled-translational-immuno-oncology-biomarkers-on-april-8th2022-05-04T21:03:24-07:00weekly0.5https://imaginab.com/news-events/event/imaginab-attending-aacr-annual-meeting-20222022-04-05T15:29:32-07:00weekly0.5https://imaginab.com/news-events/event/anna-wu-phd-to-present-cd8-immunopet-using-zr89crefmirlimab-for-imaging-responses-to-immunotherapy-at-the-tucson-symposium-on-april-5th2022-03-17T10:19:16-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-eliminates-1-7k-hours-of-ap-workload-and-the-need-to-hire-additional-headcount2022-03-15T11:02:54-07:00weekly0.5https://imaginab.com/news-events/news/shine-technologies-and-imaginab-announce-lutetium-177-clinical-supply-agreement2022-03-09T10:39:19-08:00weekly0.5https://imaginab.com/news-events/webinar/march-31-webinar-22025-05-01T06:03:13-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-inc-and-dongcheng-pharmaceutical-partnership2022-01-25T23:59:15-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-formally-launches-phase-iib-ipredict-study-to-prove-cd8-immunopet-imaging-predictivity2022-01-20T19:46:31-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-major-expansion-of-pipeline-as-it-extends-into-radiopharmaceutical-therapies-rpt-to-address-unmet-needs-in-oncology2022-01-07T09:03:23-08:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-license-and-supply-agreement-with-bayer-for-cd8-immunopet-technology2021-12-16T09:05:23-08:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/og.jpgImaginAbhttps://imaginab.com/news-events/event/jpmorgan-health-care-conference2021-12-08T09:17:51-08:00weekly0.5https://s3.us-west-1.amazonaws.com/imaginab-website-assets/11202-Social_JP-Morgan-v2-2-002.jpg11202+Social+JP+Morgan+v2+2+002https://imaginab.com/news-events/event/trp-targeted-radiopharmaceuticals-summit-20212021-12-07T12:42:00-08:00weekly0.5https://imaginab.com/news-events/event/spotlight-on-the-westside-virtual-panel-discussion-ian-wilson-ceo-imaginab-joins-biocom-california-panel-tuesday-december-7th-at-10-am-pst2021-12-07T12:42:43-08:00weekly0.5https://imaginab.com/news-events/webinar/2nd-december-webinar2021-12-21T02:30:22-08:00weekly0.5https://imaginab.com/news-events/news/clinical-grade-89zr-oxine-cell-labeling2021-11-02T07:24:19-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-partnership-with-brand-institute-to-develop-a-global-brand-name-for-cd8-immunopet-technology2021-11-01T02:10:20-07:00weekly0.5https://imaginab.com/news-events/event/society-for-immunotherapy-of-cancer-20212021-10-25T21:38:06-07:00weekly0.5https://imaginab.com/news-events/news/briacell-declares-imaginabs-cd8-immunopet-as-the-holy-grail2021-10-25T21:26:38-07:00weekly0.5https://imaginab.com/news-events/event/bio-europe-digital-20212021-10-06T07:14:01-07:00weekly0.5https://imaginab.com/news-events/event/eanm-20212021-10-22T04:30:15-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-chugai-announce-new-non-exclusive-license-and-supply-agreement-for-cd8-immunopet2021-09-02T07:58:12-07:00weekly0.5https://imaginab.com/news-events/news/briacell-and-imaginab-announce-collaboration-to-evaluate-immunotherapy-imaging-technology-in-advanced-breast-cancer2021-08-19T05:39:49-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-extension-of-long-standing-partnership-with-boehringer-ingelheim2021-07-21T22:12:30-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-successful-1st-patient-dosed-in-new-immuno-oncology-clinical-trial-into-b-cell-non-hodgkins-lymphoma2021-07-15T09:39:49-07:00weekly0.5https://imaginab.com/news-events/news/abcuro-and-imaginab-share-initial-results-of-study-using-novel-technology-for-imaging-t-cell-infiltration-of-skeletal-muscle-in-patients-with-inclusion-body-myositis2021-06-30T07:21:14-07:00weekly0.5https://imaginab.com/news-events/news/innovative-method-to-improve-cancer-immunotherapy-university-hospital-t%C3%BCbingen-cooperates-with-imaginab-and-is-europes-first-center-for-the-production-of-radiolabeled-cd8-minibodies2021-06-22T08:20:11-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-completes-12-8-million-financing-to-accelerate-growth-plans2021-06-08T02:00:40-07:00weekly0.5https://imaginab.com/news-events/event/snmmi2021-virtual-annual-meeting2021-06-08T05:22:47-07:00weekly0.5https://imaginab.com/news-events/event/bio-digital-partnering-20212021-06-08T05:24:27-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-inc-forms-european-subsidiary-and-appoints-general-manager-europe2021-06-08T13:37:47-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-neuvogen-announce-licensing-agreement-for-cd8-immunopet-technology2021-06-08T05:27:04-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology2021-06-08T13:39:12-07:00weekly0.5https://imaginab.com/news-events/news/clarity-pharmaceuticals-and-imaginab-to-collaborate-on-new-cancer-targets2021-06-08T13:41:05-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-artms-announce-strategic-partnership-for-innovative-manufacture-of-89zr-cd8-immunopet-agent2021-06-08T13:42:18-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-licensing-deal-with-astrazeneca-for-cd8-immunopet-technology2021-06-08T13:42:48-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-initiates-phase-ii-clinical-trial-at-penn-medicine2021-06-08T13:44:02-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-signs-multi-party-collaboration-agreement-with-global-pharmaceutical-companies-furthering-clinical-development-companys-cd8-immunopet-technology2021-06-11T06:14:45-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-to-present-at-innovation-showcase-2019-hosted-by-the-lundquist-institute2021-06-08T13:46:08-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-publication-of-data-on-first-in-human-imaging-in-patients-with-solid-malignancies-in-the-journal-of-nuclear-medicine-22021-06-11T06:24:08-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-participation-in-innovative-medicines-initiative-immune-cells-in-the-spotlight2021-06-08T13:48:31-07:00weekly0.5https://imaginab.com/news-events/news/dr-james-allisons-gripping-documentary-breakthrough2021-06-08T13:49:44-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-enrolls-first-patient-at-the-university-of-alabama-at-birmingham-in-on-going-base-line-on-therapy-bot-phase-ii-clinical-trial2021-06-08T13:50:32-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-to-present-at-upcoming-investor-and-scientific-conferences-in-september-october-20192021-06-08T13:51:30-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-initiates-phase-ii-clinical-trial-at-a-world-leading-cancer-center2021-06-08T13:52:29-07:00weekly0.5https://imaginab.com/news-events/news/iimaginab-announces-collaboration-on-cd8-imaging-agent-with-roche2021-06-11T06:20:11-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-will-attend-and-present-at-the-upcoming-society-of-nuclear-medicine-and-molecular-imaging-snmmi-annual-meeting-being-held-june-22-25-2019-at-the-anaheim-convention-center-anaheim-califo2021-06-11T06:30:45-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-to-present-at-upcoming-investor-and-scientific-conferences-in-may-and-june-20192021-06-08T13:57:00-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-enrolls-first-patient-in-phase-ii-clinical-trial-at-a-world-leading-cancer-center-in-los-angeles-county2021-06-08T13:57:50-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-to-present-at-upcoming-investor-and-scientific-conferences-in-april-and-may-20192021-06-08T13:58:51-07:00weekly0.5https://imaginab.com/news-events/news/aacr-elects-imaginab-science-advisory-board-member-dr-antoni-ribas-as-president-elect-at-2019-annual-meeting2021-06-08T14:00:29-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-to-present-at-the-american-association-for-cancer-research-annual-meeting-20192021-06-08T14:01:19-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-change-in-management-and-strengthening-of-the-board-of-directors-and-the-scientific-advisory-board2021-06-08T14:08:04-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-enrolls-first-patient-in-phase-ii-clinical-trial2021-06-08T14:03:42-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-immuno-oncology-license-and-clinical-trial-collaboration-with-nektar-therapeutics2021-06-08T14:04:40-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-announces-strengthening-of-board-and-executive-leadership-team2021-06-11T06:28:00-07:00weekly0.5https://imaginab.com/news-events/news/collaboration-with-merck-imaging-agent2021-06-08T14:06:11-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-and-cpdc-make-announcement2021-06-11T06:25:27-07:00weekly0.5https://imaginab.com/news-events/news/new-appointments-to-scientific-advisory-board2021-06-11T06:29:25-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-reconstitutes-japanese-subsidiary2021-06-08T14:13:08-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-reconstitutes-scientific-advisory-board2021-06-08T14:14:13-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-appoints-ian-wilson-as-chief-operating-officer2021-06-08T14:15:55-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-closes-8-million-new-funding-to-accelerate-clinical-development-of-cd8-immunopet-agent2021-06-08T14:16:53-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-inc-announces-strategic-collaboration-with-boehringer-ingelheim-to-develop-new-technology-for-monitoring-anti-tumor-activity-of-the-immune-system2021-06-08T14:17:52-07:00weekly0.5https://imaginab.com/news-events/news/imaginab-appoints-martyn-coombs-as-new-chief-executive-officer2021-06-08T14:18:54-07:00weekly0.5